Ginkgo Bioworks Holdings Inc vs Trade Desk Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while Trade Desk Inc trades at $19.17 (market cap $8.90B). The key difference: Trade Desk Inc is far larger — about 15.1× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Trade Desk Inc nearer its low. Which is the better fit depends on your goals.
| DNA | TTD | |
|---|---|---|
Market Cap | $590.53M | $8.90B |
Sector | Health | Technology |
52-Week High | $16.14 | $89.76 |
52-Week Low | $5.48 | $17.33 |
Enterprise Value | $627.78M | $7.92B |
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
The Trade Desk (TTD) trades at $19.79, up 1.33% with a mixed technical picture showing bullish overall signals but bearish moving averages. Fundamentally, the company maintains strong profitability with 77.83% gross margins and 14.57% net income margin, though revenue growth has slowed from 25% to 12% guidance. Recent developments include new data partnerships in Japan and board appointments, while settling the Publicis dispute removes a key headwind.
TTD presents a value opportunity trading below consensus targets with strong cash flow generation, but faces growth deceleration and competitive pressures. The stock's 52% decline year-to-date reflects market concerns about market share loss to walled gardens, though aggressive share repurchases and attractive valuation multiples support potential upside if growth stabilizes.
Trailing returns across standard periods
Latest headlines on both assets
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →